Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season
<p><strong>Background</strong></p> Influenza virus presents a considerable challenge to public health by causing seasonal epidemics and occasional pandemics. Nanopore metagenomic sequencing has the potential to be deployed for near-patient testing, providing rapid infection d...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
European Centre for Disease Prevention and Control
2021
|
| _version_ | 1797069535680921600 |
|---|---|
| author | Xu, Y Lewandowski, K Downs, LO Kavanagh, J Hender, T Lumley, S Jeffery, K Foster, D Sanderson, ND Vaughan, A Morgan, M Vipond, R Carroll, C Peto, T Crook, D Walker, AS Matthews, PC Pullan, ST |
| author_facet | Xu, Y Lewandowski, K Downs, LO Kavanagh, J Hender, T Lumley, S Jeffery, K Foster, D Sanderson, ND Vaughan, A Morgan, M Vipond, R Carroll, C Peto, T Crook, D Walker, AS Matthews, PC Pullan, ST |
| author_sort | Xu, Y |
| collection | OXFORD |
| description | <p><strong>Background</strong></p>
Influenza virus presents a considerable challenge to public health by causing seasonal epidemics and occasional pandemics. Nanopore metagenomic sequencing has the potential to be deployed for near-patient testing, providing rapid infection diagnosis, rationalising antimicrobial therapy, and supporting infection-control interventions.
<p><strong>Aim</strong></p>
To evaluate the applicability of this sequencing approach as a routine laboratory test for influenza in clinical settings.
<p><strong>Methods</strong></p>
We conducted Oxford Nanopore Technologies (Oxford, United Kingdom (UK)) metagenomic sequencing for 180 respiratory samples from a UK hospital during the 2018/19 influenza season, and compared results to routine molecular diagnostic standards (Xpert Xpress Flu/RSV assay; BioFire FilmArray Respiratory Panel 2 assay). We investigated drug resistance, genetic diversity, and nosocomial transmission using influenza sequence data.
<p><strong>Results</strong></p>
Compared to standard testing, Nanopore metagenomic sequencing was 83% (75/90) sensitive and 93% (84/90) specific for detecting influenza A viruses. Of 59 samples with haemagglutinin subtype determined, 40 were H1 and 19 H3. We identified an influenza A(H3N2) genome encoding the oseltamivir resistance S331R mutation in neuraminidase, potentially associated with an emerging distinct intra-subtype reassortant. Whole genome phylogeny refuted suspicions of a transmission cluster in a ward, but identified two other clusters that likely reflected nosocomial transmission, associated with a predominant community-circulating strain. We also detected other potentially pathogenic viruses and bacteria from the metagenome.
<p><strong>Conclusion</strong></p>
Nanopore metagenomic sequencing can detect the emergence of novel variants and drug resistance, providing timely insights into antimicrobial stewardship and vaccine design. Full genome generation can help investigate and manage nosocomial outbreaks. |
| first_indexed | 2024-03-06T22:25:54Z |
| format | Journal article |
| id | oxford-uuid:56a949dd-6096-4e23-9e2f-490f90e1e1a5 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:25:54Z |
| publishDate | 2021 |
| publisher | European Centre for Disease Prevention and Control |
| record_format | dspace |
| spelling | oxford-uuid:56a949dd-6096-4e23-9e2f-490f90e1e1a52022-03-26T16:51:53ZNanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza seasonJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:56a949dd-6096-4e23-9e2f-490f90e1e1a5EnglishSymplectic ElementsEuropean Centre for Disease Prevention and Control2021Xu, YLewandowski, KDowns, LOKavanagh, JHender, TLumley, SJeffery, KFoster, DSanderson, NDVaughan, AMorgan, MVipond, RCarroll, CPeto, TCrook, DWalker, ASMatthews, PCPullan, ST<p><strong>Background</strong></p> Influenza virus presents a considerable challenge to public health by causing seasonal epidemics and occasional pandemics. Nanopore metagenomic sequencing has the potential to be deployed for near-patient testing, providing rapid infection diagnosis, rationalising antimicrobial therapy, and supporting infection-control interventions. <p><strong>Aim</strong></p> To evaluate the applicability of this sequencing approach as a routine laboratory test for influenza in clinical settings. <p><strong>Methods</strong></p> We conducted Oxford Nanopore Technologies (Oxford, United Kingdom (UK)) metagenomic sequencing for 180 respiratory samples from a UK hospital during the 2018/19 influenza season, and compared results to routine molecular diagnostic standards (Xpert Xpress Flu/RSV assay; BioFire FilmArray Respiratory Panel 2 assay). We investigated drug resistance, genetic diversity, and nosocomial transmission using influenza sequence data. <p><strong>Results</strong></p> Compared to standard testing, Nanopore metagenomic sequencing was 83% (75/90) sensitive and 93% (84/90) specific for detecting influenza A viruses. Of 59 samples with haemagglutinin subtype determined, 40 were H1 and 19 H3. We identified an influenza A(H3N2) genome encoding the oseltamivir resistance S331R mutation in neuraminidase, potentially associated with an emerging distinct intra-subtype reassortant. Whole genome phylogeny refuted suspicions of a transmission cluster in a ward, but identified two other clusters that likely reflected nosocomial transmission, associated with a predominant community-circulating strain. We also detected other potentially pathogenic viruses and bacteria from the metagenome. <p><strong>Conclusion</strong></p> Nanopore metagenomic sequencing can detect the emergence of novel variants and drug resistance, providing timely insights into antimicrobial stewardship and vaccine design. Full genome generation can help investigate and manage nosocomial outbreaks. |
| spellingShingle | Xu, Y Lewandowski, K Downs, LO Kavanagh, J Hender, T Lumley, S Jeffery, K Foster, D Sanderson, ND Vaughan, A Morgan, M Vipond, R Carroll, C Peto, T Crook, D Walker, AS Matthews, PC Pullan, ST Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season |
| title | Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season |
| title_full | Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season |
| title_fullStr | Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season |
| title_full_unstemmed | Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season |
| title_short | Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season |
| title_sort | nanopore metagenomic sequencing of influenza virus directly from respiratory samples diagnosis drug resistance and nosocomial transmission united kingdom 2018 19 influenza season |
| work_keys_str_mv | AT xuy nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason AT lewandowskik nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason AT downslo nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason AT kavanaghj nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason AT hendert nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason AT lumleys nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason AT jefferyk nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason AT fosterd nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason AT sandersonnd nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason AT vaughana nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason AT morganm nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason AT vipondr nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason AT carrollc nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason AT petot nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason AT crookd nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason AT walkeras nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason AT matthewspc nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason AT pullanst nanoporemetagenomicsequencingofinfluenzavirusdirectlyfromrespiratorysamplesdiagnosisdrugresistanceandnosocomialtransmissionunitedkingdom201819influenzaseason |